FrancophonIA/ELRC3.0 huggingface dataset:
English: SD = standard deviation; SE = standard error; LS Mean = least-squares mean; CI = confidence interval; AD = antidepressant
Croatian: ANCOVA (analysis of covariance) = analiza kovarijance; BOCF (baseline observation carried forward) = prijenos početno zabilježene vrijednosti; SD (standard deviation) = standardno odstupanje; SE (standard error) = standardna pogreška; LS (least squares) = metoda najmanjih kvadrata; CI (confidence interval) = interval pouzdanosti; AD = antidepresiv Esketamin ili placebo primijenjeni nazalno; oralni AD = novouvedeni antidepresiv (SNRI: duloksetin, venlafaksin s produljenim oslobađanjem; SSRI: escitalopram, sertralin)
English: Do not blow nose.
Croatian: Bolesnik ne smije ispuhati nos.
English: Post-administration observation
Croatian: Promatranje nakon primjene
English: Finger rest
Croatian: Hvatište za prste
English: NASAL SPRAY/DEVICE LABEL
Croatian: Tablični prikaz nuspojava
English: Spravato dosages were then maintained on 56 mg or titrated to 84 mg or matching placebo nasal spray administered twice-weekly during a 4-week double-blind induction phase.
Croatian: Zatim su primali Spravato u dozi koja se održavala na 56 mg ili titrirala do 84 mg, odnosno odgovarajuću dozu placeba u spreju za nos, dvaput tjedno tijekom 4-tjedne dvostruko slijepe faze uvodnog liječenja.
English: These can occur with high doses of a similar medicine (called ketamine) used over a long period.
Croatian: • bol pri mokrenju ili krv u mokraći - to mogu biti znakovi tegoba s mokraćnim mjehurom, koje se mogu javiti kod dugoročne primjene visokih doza jednog sličnog lijeka (koji se zove ketamin).
English: ● After the first 4 weeks, Spravato is usually used once a week
Croatian: Spravato se obično primjenjuje jedanput tjedno.
English: First dose was Spravato 56 mg + oral AD
Croatian: Prva je doza bila 56 mg lijeka Spravato + oralni antidepresiv
English: Relapse-prevention study
Croatian: Ispitivanje lijeka Spravato u prevenciji relapsa
English: Starting day 1 dose: 56 mg Subsequent doses: 56 mg or 84 mg twice a week
Croatian: Početna doza (1. dan): 56 mg Sljedeće doze:
English: ● muscle tremors
Croatian: • nevoljno drhtanje mišića
English: 1 nasal spray device 6 nasal spray devices
Croatian: 1 sprej za nos 6 sprejeva za nos
English: Respiratory, thoracic and mediastinal disorders nasal discomfort, nasal dryness including nasal crusting, nasal pruritus
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja nelagoda u nosu, suhoća nosa uključujući stvaranje krasti u nosu, svrbež
English: Nasal sprays
Croatian: Prijavljivanje nuspojava
English: A newly initiated open-label oral AD (SNRI: duloxetine, venlafaxine extended release; SSRI: escitalopram, sertraline) was initiated on day 1 in all studies.
Croatian: U svim je ispitivanjima 1. dana započelo otvoreno liječenje novouvedenim oralnim antidepresivom (SNRI: duloksetin, venlafaksin s produljenim oslobađanjem; SSRI: escitalopram, sertralin).
English: Investigations blood pressure increased
Croatian: Pretrage povišen krvni tlak
English: Dose-dependent increases in the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC∞) of esketamine nasal spray were produced by doses of 28 mg, 56 mg and 84 mg.
Croatian: Kod primjene doza od 28 mg, 56 mg i 84 mg esketamina u spreju za nos zabilježena su o dozi ovisna povećanja maksimalne plazmatske koncentracije lijeka (Cmax) i područja ispod krivulje plazmatske koncentracije kroz vrijeme (AUC∞).
English: ● blurred vision
Croatian: • zamagljen vid
English: Talk to your doctor before using Spravato if you are breast-feeding.
Croatian: Ako dojite, razgovarajte sa svojim liječnikom prije nego primijenite Spravato.
English: Spravato (28 mg, 56 mg or
Croatian: Spravato (28 mg, 56 mg ili 84 mg) + oralni AD
English: Spravato dosages were titrated to 56 mg or 84 mg or matching placebo nasal spray administered twice-weekly during a 4-week double-blind induction phase.
Croatian: Bolesnici su primali Spravato u dozi koja se titrirala do 56 mg ili 84 mg, odnosno odgovarajuću dozu placeba u spreju za nos, dvaput tjedno tijekom 4-tjedne dvostruko slijepe faze uvodnog liječenja.
English: What Spravato looks like and contents of the pack Spravato is a nasal spray solution.
Croatian: Kako Spravato izgleda i sadržaj pakiranja
English: ● nausea
Croatian: • uznemirenost
English: ● feeling dizzy
Croatian: • suha usta
English: ● feeling sleepy
Croatian: • omaglica
English: Female
Croatian: nosa
English: Section 2 - What you need to know before you <take> <use> X:
Croatian: Dio 2 - Što morate znati prije nego počnete <uzimati> <primjenjivati> X
English: If this happens, you should contact your doctor immediately.”
Croatian: Ako se to dogodi, odmah se obratite liječniku.“
English: ”Inhibitors
Croatian: „Inhibitori
English: Of the 22, 10 were high titre (≥ 5 Bethesda Units) and 12 were low titre (< 5 Bethesda Units).
Croatian: Od njih 22, 10 je imalo visoki titar (≥ 5 Bethesda jedinica), a 12 niski titar (< 5 Bethesda jedinice).
English: Uncommon (PTPs) *
Croatian: manje često (PTPs) *
English: The product information may be subsequently updated by the Member State competent authorities, in liaison with the reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Croatian: Informacije o lijeku mogu naknadno ažurirati nadležna tijela država članica, gdje je prikladno u suradnji s referentnom državom članicom, u skladu s postupcima navedenima u Poglavlju 4. Glave III Direktive 2001/83/EZ.
English: The safety and efficacy of {(Invented) name} in previously untreated patients have not yet been established.
Croatian: Sigurnost i djelotvornost lijeka {(novoizumljeno) ime} u prethodno neliječenih bolesnika još nije ustanovljena.
English: Uncommon (PTPs)* Very common (PUPs)*
Croatian: manje često (PTPs)* vrlo često (PUPs)*
English: Inhibitor Development
Croatian: Razvoj inhibitora
English: Section 4 - Possible side effects:
Croatian: Dio 4 - Moguće nuspojave
English: These amendments to the relevant sections of the product information are the outcome of the referral procedure.
Croatian: Ove dopune odgovarajućih dijelova informacija o lijeku ishod su arbitražnog postupka.
English: In the PTPT clinical trial (PTP - previously treated patients), none of the 71 subjects developed a de novo FVIII antibody, but 22 of 72 evaluable per protocol PUPs (PUP - previously untreated patients) treated with Recombinate did develop FVIII antibodies and the above frequency was based on the PUP data.
Croatian: U kliničkom ispitivanju PTPT (PTP - prethodno liječeni bolesnici), nijedan od 71 ispitanika nije razvio de-novo antitijela na FVIII, ali 22 od 72 PUPs ocjenjivih po planu ispitivanja (PUP - prethodno neliječeni bolesnici) koji su liječeni lijekom Recombinate razvila su antitijela na FVIII, a prethodno navedena učestalost temeljila se na podacima za PUP.
English: If you or your child´s bleeding is not being controlled with <product name>, tell your doctor immediately.”
Croatian: Vašeg djeteta ne može kontrolirati pomoću lijeka <naziv lijeka>, odmah se obratite liječniku.“
English: For all products listed in Annex I, the existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below.
Croatian: Za sve lijekove navedene u Prilogu I., postojeće informacije o lijeku bit će nadopunjene (umetanje, zamjena ili brisanje teksta, prema potrebi) kako bi bila u skladu s dogovorenim tekstom kako je navedeno u nastavku.
English: Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.”
Croatian: Liječenje takvih bolesnika trebaju voditi liječnici s iskustvom u liječenju hemofilije i inhibitora faktora VIII.“
English: >“), all existing information on inhibitor development should be replaced with the following:
Croatian: >“), sve postojeće informacije o razvoju inhibitora trebaju se zamijeniti sljedećim:
English: If this happens you or your child´s medicines may stop working properly and you or your child may experience persistent bleeding.
Croatian: U tom slučaju Vaš lijek ili lijek Vašeg dijeteta može prestati ispravno djelovati, a kod Vas ili Vašeg djeteta može se javiti krvarenje koje ne prestaje.
English: ”Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with <product name> < see section 5.1>.
Croatian: „Do razvoja neutralizirajućih antitijela (inhibitora) može doći u bolesnika s hemofilijom A koji su liječeni faktorom VIII, uključujući <naziv lijeka> < , vidjeti dio 5.1>.
English: [[For all products listed in Annex I] the wording should be revised as follows:] “The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all Factor VIII medicines.
Croatian: [[Za sve lijekove navedene u Prilogu I.] tekst treba revidirati na sljedeći način:] „Stvaranje inhibitora (antitijela) poznata je komplikacija koja se može pojaviti tijekom liječenja bilo kojim lijekom koji sadrži faktor VIII.
English: • For products where a study in PUPs is required but results are not yet available (i.e. products not authorised in PUPs and for which section 4.2 contains the following statement for PUPs (“<Previously untreated patients.
Croatian: • Za lijekove kod kojih je potrebno ispitivanje u prethodno neliječenih bolesnika ali rezultati još nisu dostupni (odnosno, lijekovi nisu odobreni za prethodno neliječene bolesnike i za koje dio 4.2 sadrži sljedeću izjavu za prethodno neliječene bolesnike (“<prethodno neliječeni bolesnici.
English: The reported incidence of inhibitory antibodies in patients with severe haemophilia A who are at high risk for inhibitors development (i.e. previously untreated patients) is estimated in studies to be 31% for Recombinate, which is within the reported range for plasma derived AHF.
Croatian: Zabilježena incidencija inhibitornih antitijela u bolesnika s teškom hemofilijom A, koji su izloženi visokom riziku za razvoj inhibitora (tj. bolesnici koji nisu prije primali nadomjesno liječenje (PUP)) procijenjena je u ispitivanjima 31% za Recombinate, što je unutar zabilježenog raspona za faktore VIII dobivene iz plazme.
English: • For the remaining products (i.e. products authorised in PUPs), all existing information on inhibitor development should be replaced with the following:
Croatian: • Za ostale lijekove (odnosno, lijekove odobrene za PUPs), sve postojeće informacije o razvoju inhibitora potrebno je zamijeniti sljedećim:
English: • [[For products listed in Annex I for which a frequency for PUPs has been implemented in section 4.8 of the SmPC] the wording should be revised as follows:] “For children not previously treated with Factor VIII medicines, inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10 patients); however patients who have received previous treatment with Factor VIII (more than 150 days of treatment) the risk is uncommon (less than 1 in 100 patients).
Croatian: • [[Za lijekove navedene u Prilogu I. za koje je učestalost za PUPs implementirana u dio 4.8 sažetka opisa svojstava] tekst treba revidirati na sljedeći način:] „U djece koja ranije nisu bila liječena lijekovima koji sadrže faktor VIII, vrlo često (u više od 1 na 10 bolesnika) mogu nastati inhibitorna antitijela (vidjeti dio 2); međutim, u bolesnika koji su ranije primali terapiju s faktorom VIII (više od 150 dana liječenja) rizik je manje čest (manje od 1 na 100 bolesnika).
English: Amendments to the product information
Croatian: Dopune informacija o lijeku
English: The risk of developing inhibitors is correlated to the exposure to Antihaemophilic Factor VIII, this risk being highest within the first 20 exposure days.
Croatian: Rizik od razvijanja inhibitora povezan je s izlaganjem faktoru VIII, a najveći je unutar prvih 20 dana izlaganja.
English: • [[For products listed in Annex I for which a frequency for PUPs has not been implemented in section 4.8 of the SmPC] the wording should be revised as follows:] “For patients who have received previous treatment with Factor VIII (more than 150 days of treatment) inhibitor antibodies (see section 2) may form uncommonly (less than 1 in 100 patients).
Croatian: • [[Za lijekove navedene u Prilogu I. za koje učestalost za PUPs nije implementirana u dio 4.8 sažetka opisa svojstava] tekst treba revidirati na sljedeći način:] „Za bolesnike koji su primali raniju terapiju s faktorom VIII (više od 150 dana liječenja) inhibitorna antitijela (vidjeti dio 2) mogu se stvarati manje često (manje od 1 na 100 bolesnika).
English: (Any reference to inhibitor development studies in PUPs and PTPs in section 4.8 of the SmPC should be deleted.)
Croatian: (Treba izbrisati sve navode o ispitivanjima razvoja inhibitora u prethodno neliječenih bolesnika i prethodno liječenih bolesnika u dijelu 4.8 sažetka opisa svojstava lijeka.)
English: * Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients”
Croatian: • Ova fusnota treba se navesti na dnu tablice uz primjenu kratice prema potrebi: * Učestalost se temelji na ispitivanjima sa svim lijekovima s FVIII koja su uključivala bolesnike s teškom hemofilijom A. PTPs = prethodno liječeni bolesnici (engl. previously-treated patients), PUPs = prethodno neliječeni bolesnici (engl. previously-untreated patients)“
English: ([For all products listed in Annex I] the wording should be revised as follows: all existing information on inhibitor development should be replaced with the following)
Croatian: ([Za sve lijekove navedene u Prilogu I.] tekst treba revidirati na sljedeći način: sve postojeće informacije o razvoju inhibitora trebaju se zamijeniti sljedećim)
English: B. Package leaflet [[For all products listed in Annex I] the following texts should be added to or replace existing texts, as appropriate:]
Croatian: Uputa o lijeku [[Za sve lijekove navedene u Prilogu I.] sljedeći tekst treba dodati ili zamijeniti postojeći tekst prema potrebi:]
English: Section 5.1 - Pharmacodynamic properties (In accordance with the PRAC recommendation, existing relevant text in section 5.1 of the SmPC in relation to inhibitor frequency for Recombinate should be deleted.)
Croatian: (U skladu s preporukama PRAC-a, potrebno je izbrisati postojeći odgovarajući tekst u dijelu 5.1 sažetka opisa svojstava lijeka u vezi s učestalošću inhibitora za lijek Recombinate.)
English: ([For all products listed in Annex I] all existing information on inhibitor development should be replaced with the following)
Croatian: ([Za sve lijekove navedene u Prilogu I.] sve postojeće informacije o razvoju inhibitora trebaju se zamijeniti sljedećim)
English: B-1800 Vilvoorde
Croatian: B-1800 Vilvoorde Belgium
English: LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Croatian: POPIS NAZIVA, FARMACEUTSKIH OBLIKA, JAČINA LIJEKOVA, PUTEVA PRIMJENE,
English: D-90429 Nürnberg Germany
Croatian: D-90429 Nürnberg
English: National Road No. 1 (12th Km) Metamorphosis
Croatian: 1 (12th Km) Metamorphosis
English: Novartis Finland OY Metsänneidonkuja 10 FI-02130 Espoo Finland
Croatian: Metsänneidonkuja 10 FI-02130 Espoo Finland
English: Denmark Novartis Healthcare A/S Lyngbyvej 172
Croatian: Novartis Healthcare A/S Lyngbyvej 172
English: Novartis Farmacéutica S.A. Gran Via de les Corts Catalanes,
Croatian: Španjolska Novartis Farmacéutica S.A. Gran Via de les Corts Catalanes,
English: Belgium N.V. Novartis Pharma S.A. Medialaan 40, bus 1
Croatian: Novartis Pharma S.A. Medialaan 40, bus 1
English: 2-4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
Croatian: Novartis Pharma S.A.S. 2-4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
English: 2- 4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
Croatian: Novartis Pharma S.A.S. 2- 4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
English: Netherlands Novartis Pharma B.V. Raapopseweg 1
Croatian: Nizozemska Novartis Pharma B.V.
English: Intravenous
Croatian: U venu
English: ANNEX I
Croatian: Raapopseweg 1
English: 250 mg/5 ml Concentrate for solution for infusion
Croatian: 250 mg/5 ml Koncentrat za otopinu za infuziju
English: 0.270 mL(833 IU/mL) 1 cartridge + 1 pack with 3 pen needles
Croatian: Veličina pakovanja uložak (staklo) 0,270 ml (833 IU/ml) 1 uložak + 1 pakiranje s 3 igle za brizgalicu
English: Nearly all patients also took aspirin and/or other blood-thinning medicines.
Croatian: Gotovo svi bolesnici uzimali su aspirin i/ili druge lijekove za razrjeđivanje krvi.
English: Treatment should be started before the PCI procedure, and the infusion should be continued for at least 2 hours or until the procedure is over, whichever is longer.
Croatian: Terapiju treba započeti prije postupka PCI-a, a infuziju treba nastaviti najmanje tijekom 2 sata ili dok se postupak ne završi, ovisno o tome što dulje traje.
English: Treatment starts with an injection into a vein at a dose of 30 micrograms per kilogram bodyweight, which should last less than a minute; this is followed immediately after by an infusion at a rate of 4 micrograms per kilogram each minute.
Croatian: Terapija započinje injekcijom u venu u dozi od 30 mikrograma po kilogramu tjelesne mase, koja treba trajati manje od minute; neposredno nakon toga slijedi infuzija u stopi od 4 mikrograma po kilogramu svake minute.
English: At the discretion of the doctor, the infusion may be continued for up to four hours.
Croatian: Ukoliko liječnik odluči, infuzija se može nastaviti i tijekom četiri sata.
English: Kengrexal was shown to be more effective than clopidogrel taken by mouth at reducing the occurrence of these events: 4.7% of patients (257 out of 5,470 patients) given Kengrexal had an event or died compared with 5.9% (322 out of 5,469 patients) of patients given clopidogrel.
Croatian: Utvrđeno je da je Kengrexal djelotvorniji od klopidogrela kada se uzima peroralno u smanjivanju nastupanja sljedećih događaja: Kod 4,7% bolesnika (257 od 5.470 bolesnika), koji su primili Kengrexal, zabilježen je poremećaj ili su preminuli, u usporedbi s 5,9% (322 od 5.469 bolesnika) bolesnika koji su primili klopidogrel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kengrexal on 23 March 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Kengrexal na snazi u Europskoj uniji od 23. ožujka 2015.
English: This is a summary of the European public assessment report (EPAR) for Kengrexal.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Kengrexal.
English: Why is Kengrexal approved?
Croatian: Zašto je Kengrexal odobren?
English: The main measure of effectiveness was based on the number of patients having an ‘event' such as a heart attack or clots in the heart blood vessels requiring intervention, or dying from any cause, in the 48 hours following PCI.
Croatian: Glavna mjera djelotvornosti temeljila se na broju bolesnika koji su iskusili poremećaj poput zastoja srca ili ugrušaka u srčanim krvnim žilama, koji je zahtijevao intervenciju ili koji su umirali od bilo kojeg uzroka unutar 48 sati nakon PCI-a.
English: However, the way this study was designed was considered inadequate to show a clear benefit in these patients, and the company did not pursue this use as part of the application.
Croatian: No, zaključeno je da je način provođenja ispitivanja neprimjeren za utvrđivanje jasne koristi u ovih bolesnika, a tvrtka nije inzistirala na ovaj primjeni u sklopu svoje prijave.
English: The medicine can only be obtained with a prescription and should be given in a hospital setting.
Croatian: Lijek se izdaje samo na liječnički recept i treba se primjenjivati u bolničkom okruženju.
English: What measures are being taken to ensure the safe and effective use of Kengrexal?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kengrexal?
English: Regarding Kengrexal's safety profile, the CHMP noted that the incidence of bleeding was higher for Kengrexal than for clopidogrel, but this was expected given the greater effectiveness of the medicine, and was offset by the fact that the activity of Kengrexal wore off quickly once the infusion was stopped.
Croatian: Vezano uz sigurnosni profil lijeka Kengrexal, CHMP je zaključio kako je incidencija krvarenja veća s lijekom Kengrexal u odnosu na klopidogrel, no to je bilo očekivano uzimajući u obzir veću djelotvornost lijeka, a nadoknađeno je činjenicom da je djelovanje lijeka Kengrexal brzo oslabilo nakon što je infuzija prekinuta.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kengrexal's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Kengrexal nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: What is Kengrexal and what is it used for?
Croatian: Što je Kengrexal i za što se koristi?
English: It must also not be used in patients who have had a stroke or mini stroke (transient ischaemic attack or TIA).
Croatian: Ne smije se također koristiti u bolesnika koji su imali moždani udar ili mali moždani udar (tranzitorni ishemijski atak (TIA)).
English: It is used together with aspirin in adults with coronary artery disease (heart disease caused by the obstruction of the blood vessels that supply the heart) who are undergoing percutaneous coronary intervention (PCI - a surgical procedure used to unblock narrowed blood vessels that supply the heart).
Croatian: Koristi se zajedno s aspirinom u odraslih osoba s koronarnom arterijskom bolešću(srčanom bolešću koja je uzrokovana opstrukcijom krvnih žila koje opskrbljuju srce), koji se podvrgavaju perkutanim koronarnim intervencijama (PCI-u - kirurškom postupku koji se koristi za deblokiranje suženih krvnih žila koje opskrbljuju srce).
English: The fact that the medicine is given into a vein is considered useful in patients who cannot swallow and cannot take treatments by mouth.
Croatian: Činjenica da se lijek primjenjuje u venu smatra se korisnom u bolesnika koji ne mogu gutati ili terapiju ne mogu primiti na usta.
English: The medicine has been shown to be beneficial at reducing problems caused by blood clots in patients undergoing PCI who have not received previous treatment with P2Y12 inhibitors.
Croatian: Utvrđeno je da je lijek koristan u smanjivanju problema uzrokovanih krvnim ugrušcima u bolesnika koji su podvrgnuti PCI-u, a koji nisu primili prethodnu terapiju s inhibitorima P2Y12.
English: Kengrexal must not be used in patients who are actively bleeding or who are at an increased risk of bleeding because of a bleeding disorder, recent major surgery or trauma, or uncontrolled high blood pressure.
Croatian: Kengrexal se ne smije koristiti u bolesnika koji aktivno krvare ili su izloženi prevelikom riziku od krvarenja zbog poremećaja krvarenja, nedavnog većeg kirurškog zahvata ili traume, odnosno nekontroliranog visokog krvnog tlaka.
English: Kengrexal is given to patients who have not been treated before the procedure with other blood-thinning medicines called ‘P2Y12 inhibitors' (clopidogrel, ticagrelor or prasugrel) taken by mouth, and for whom treatment with these medicines is not possible or desirable.
Croatian: Kengrexal se primjenjuje u bolesnika koji nisu prije zahvata liječeni drugim lijekovima za razrjeđivanje krvi naziva "inhibitor receptora P2Y12" (klopidogrel, tikagrelor ili prasugrel) koji se uzimaju peroralno te za koje terapija ovakvim lijekovima nije moguća niti poželjna.
English: This means that it helps to prevent blood cells called platelets from sticking together and forming blood clots, thus helping to prevent another heart attack.
Croatian: To znači da pomaže u sprječavanju toga da se crvene stanice naziva trombociti lijepe zajedno i formiraju krvne ugruške, te tako pomaže u sprječavanju novog srčanog zastoja.